
IDO, serotonin and melatonin in interaction in depressive disorders
Modern research into the development of depressive disorders is increasingly recognizing that, in addition to psychological factors, biological factors also play a crucial role. A central biochemical approach is tryptophan metabolism, which encompasses not only the synthesis of neurotransmitters such as serotonin, but also the formation of other active metabolites such as melatonin and kynurenines. The enzyme indolamine 2,3-dioxygenase (IDO), in particular, plays a key role in this process, as its increased activity promotes the degradation of tryptophan into kynurenine metabolites, which can lead to an imbalance in the neurochemical system.
1. IDO and its influence on tryptophan metabolism
IDO is predominantly expressed in monocytes and dendritic cells and is induced by proinflammatory cytokines, particularly interferon-gamma (IFN-γ). This mechanism represents a physiological defense response to impede the proliferation of invading pathogens by depriving them of the essential amino acid tryptophan. However, persistent activation of IDO can occur in chronic, TH1-dominated inflammation or in the context of interferon-based therapy (e.g., in HCV infections).
Increased IDO activity and its consequences:
-
Tryptophan deficiency: Due to the increased conversion of tryptophan to kynurenine, less tryptophan is available for serotonin synthesis.
-
Reduced serotonin production: Since serotonin in the central nervous system (CNS) is involved in the regulation of mood, sleep and pain, its decrease can promote depressive symptoms.
-
Formation of kynurenines: Metabolites such as quinolinic acid and 3-OH-kynurenine, which result from tryptophan degradation, have neurotoxic properties and can also cause disturbances in the neuronal control circuits.
2. Serotonin: More than just a “happiness hormone”
Serotonin plays a multifunctional role in the brain and influences numerous physiological processes:
-
Mood regulation: A lack of serotonin is often associated with depressive states.
-
Sleep-wake rhythm: By regulating sleep, serotonin contributes to a stable internal clock.
-
Pain processing and appetite: In addition to emotional regulation, serotonin is also involved in the modulation of pain perception and eating behavior.
The limitation of serotonin synthesis due to a lack of tryptophan as a result of increased IDO activity can therefore lead to a number of neurological and psychological symptoms that are typical of depressive disorders.
3. Melatonin: The sleep regulator in the context of tryptophan metabolism
The hormone melatonin is synthesized from serotonin in the pineal gland. This hormone is essential for:
-
Regulation of the circadian rhythm: Melatonin helps to control the sleep-wake cycle and adapt it to daylight conditions.
-
Antioxidant effects: Melatonin also has protective properties against oxidative stress in the nervous system.
A balanced ratio of serotonin and melatonin is therefore crucial not only for mood, but also for healthy sleep and adequate stress management. Disturbed tryptophan metabolism, caused by increased IDO activity, can also indirectly impair melatonin synthesis, leading to sleep disorders and other secondary psychological stress.
4. Therapeutic approaches and diagnostics
4.1 Tryptophan supplementation
One possible therapeutic approach for depressive symptoms is targeted tryptophan supplementation to stabilize serotonin production. However, the following must be considered:
-
No increased IDO activity: Supplementation should only be used if there is no persistent inflammatory activation that promotes tryptophan degradation towards kynurenines through increased IDO activity.
-
Low tryptophan levels: The patient's actual tryptophan status should be determined using appropriate laboratory methods.
Supplementation may be particularly useful in disorders such as fructose malabsorption, which impede the absorption of tryptophan in the intestine, provided that other metabolic activations are not present.
4.2 Anti-inflammatory therapy
Elevated serum levels of TNF-α and IFN-γ (or measurable via IP-10) indicate systemic inflammation, which can lead to IDO overactivation. In such cases, if targeted causal therapy of the inflammation is not possible, general anti-inflammatory treatment can help alleviate the depressive symptoms mediated by increased IDO activity.
Especially patients with the IFN-γ polymorphism 874T/A, who produce increased levels of IFN-γ independent of an external inflammatory stimulus, can benefit from an anti-inflammatory therapeutic approach.
4.3 Diagnostics
Modern diagnostics include:
-
Analysis of tryptophan degradation: The inflammation-induced tryptophan degradation rate is investigated in isolated blood cells.
-
Measurement of inflammatory markers: Tryptophan, IP-10 and TNF-α are determined using immunological methods to assess the extent of inflammatory activity.
-
Genetic analyses: Determination of the IFN-γ polymorphism (874T/A) by DNA sequencing provides important information on individual inflammatory predisposition.
5. Conclusion
Research clearly shows that tryptophan metabolism and its regulation via IDO play a crucial role in the development of depressive disorders. By influencing serotonin and melatonin synthesis, neurochemical imbalances arise that can contribute to the development of depressive symptoms. A differentiated diagnostic approach that considers both inflammatory parameters and genetic predispositions is therefore essential for developing targeted treatment concepts.
Therapeutic approaches range from individualized tryptophan supplementation—excluding elevated IDO activity—to anti-inflammatory measures, particularly in cases of genetically determined overproduction of IFN-γ. Ultimately, the integration of neuroendocrine-immunological aspects into clinical practice opens up new possibilities for the individualized treatment of depressive disorders.
Share:
Liver tea: A natural weapon for liver health
The fascinating connection between microbiome and neurotransmitters